Mechanism of Action of Natalizumab (Tysabri)
Introduction Natalizumab is a humanized IgG4 monoclonal antibody targeting the α4 integrin subunit. It’s approved for relapsing-remitting multiple sclerosis (RRMS) and moderate to severe Crohn’s disease. By blocking leukocyte adhesion, it prevents immune cell migration into the brain and gut. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Intravenous infusion Half-life ~11 days Distribution … Read more